Beruflich Dokumente
Kultur Dokumente
Background
Acquired hemophilia is a rare but potentially life-threatening bleeding disorder caused by the development of autoantibodies directed against plasma coagulation factors, most frequently factor VIII (FVIII).[1] Autoantibodies against other factor proteins have also been reported.[2] Because inhibitors to FVIII are the most frequently observed in clinical practice, this article focuses on the etiology and management of FVIII autoantibody inhibitors, or acquired hemophilia A. Diagnosis of acquired hemophilia can be difficult, both because the condition is rare and because the patient does not have the usual personal or family history of bleeding episodes, such as is seen in congenital hemophilia.[1] Moreover, the clinical signs and symptoms of acquired hemophilia differ from those of hereditary hemophilia. The severity of acquired hemophilia at clinical presentation can also make its management challenging. Treatment strategies for acquired hemophilia have 2 major objectives. During acute bleeding episodes, effective control of bleeding manifestations is the primary objective. However, the ultimate therapeutic goal is to eliminate the inhibitor and cure the disease. Please see the following for more information:
Pathophysiology
Acquired hemophilia is a spontaneous autoimmune disorder in which patients with previously normal hemostasis develop autoantibodies against clotting factors, most frequently FVIII.[3] The development of autoantibodies against FVIII leads to FVIII deficiency, which results in insufficient generation of thrombin by factor IXa and the factor VIIIa complex through the intrinsic pathway of the coagulation cascade. The development of factor IX (FIX) autoantibodies is less common, and the presence of autoantibodies against other clotting factorsfactors II (FII), V (FV), VII (FVII), X (FX), XI (FXI), and XIII (FXIII), as well as von Willebrand factor (vWF)is extremely rare.[3, 2, 4] The most common epitopes for autoantibody binding to FVIII appear to occur between amino acids 454-509 and 593 in the A2 domain on the heavy chain of FVIII, between 1804 and 1819 in the A3 domain on the heavy chain, and between 2181 and 2243 in the C2 domain on the light chain.[2, 5, 6] Anti-C2 antibodies inhibit the binding of FVIII to phospholipids and may also interfere with the binding of FVIII to vWF protein, whereas anti-A2 and anti-A3 antibodies impede the binding of FVIII to activated FX and FIX of the intrinsic pathway FX activation complex.[7]
Although both alloantibody inhibitors in patients with hereditary hemophilia and autoantibodies in patients with acquired hemophilia appear to recognize the same epitopes on each domain, the inactivation of FVIII resulting from these interactions differs.[8] For example, alloantibodies totally inactivate FVIII activity according to type 1 kinetics, and this total inactivation is not dependent on the titer/concentration of circulating antibody. In contrast, autoantibodies typically exhibit more complex type II kinetics, undergoing an initial rapid inactivation followed by a slower inactivation curve and resulting in some level of residual FVIII, which can be detected in the laboratory but does not seem to convey useful clinical efficacy.[8, 9]
Etiology
Acquired hemophilia results from the development of autoantibodies (mostly of immunoglobulin G [IgG] subclasses 1 and 4) directed against clotting factors.[2, 8, 4] Numerous conditions have been associated with acquired inhibitors to FVIII. Rarely, FVIII autoantibodies arise as idiosyncratic reactions to medications. However, approximately 50% of cases occur in patients who lack relevant concomitant diseases; these cases are idiopathic.
[1, 10]
Idiopathic Pregnancy Autoimmune disorders Inflammatory bowel disease, ulcerative colitis Dermatologic disorders (eg, psoriasis, pemphigus) Respiratory diseases (eg, asthma, chronic obstructive pulmonary disease) Allergic drug reactions Diabetes Acute hepatitis B infection Acute hepatitis C infection Malignancies-solid tumors (prostate, lung, colon, pancreas, stomach, bile duct, head and neck, cervix, breast, melanoma, kidney) Hematologic malignancies
Rheumatoid arthritis Systemic lupus erythematosus Multiple sclerosis Temporal arteritis Sjgren syndrome Autoimmune hemolytic anemia Goodpasture syndrome Myasthenia gravis Graves disease Autoimmune hypothyroidism
Penicillin and its derivatives Sulfamides Phenytoin Chloramphenicol Methyldopa Depot thioxanthene Interferon alfa Fludarabine Bacille Calmette-Gurin (BCG) vaccination Desvenlafaxine[11]
Chronic lymphocytic leukemia Non-Hodgkin lymphoma Multiple myeloma Waldenstrom macroglobulinemia Myelodysplastic syndrome Myelofibrosis Erythroleukemia
Table 1 below illustrates the frequency of underlying diagnoses in 3 cohort studies of patients with acquired hemophilia A.[9, 12, 13, 14, 15] (Open Table in a new window) Disease Association Green 1981 (N = Morrison 1993 (N = Collins 2007 (N = 215), % 65), % 172), % 46.1 55.0* 63.3 18.0 17.0 16.7 12.0 2.0 3.0 11.0 NR 14.7 3.3 NR 2.0 NR
Idiopathic Collagen, vascular, and other autoimmune diseases Malignancy 6.7 Skin diseases 4.5 Possible drug reaction 5.6 Pregnancy 7.3 Other 11.8 *In this trial, idiopathic and other were combined.
NRnot reported.
Disorders believed to be associated with inhibitors to coagulation factors other than FVIII are shown in the table below.[4, 16]
Table 2. Acquired Bleeding Disorders Associated With Inhibitors of Factors Other Than FVIII (Open Table in a new window) Coagulation Factor Inhibited V IX Most Commonly Associated Disorders Lymphoproliferative disorders, adenocarcinoma, tuberculosis, aminoglycosides, topical thrombin Systemic lupus erythematosus, acute rheumatic fever, hepatitis, collagen vascular diseases, multiple sclerosis, postprostatectomy, and postpartum Autoimmune diseases, prostate carcinoma, chronic lymphocytic leukemia, chlorpromazine Idiopathic, isoniazid, penicillin Autoimmune disorders, monoclonal gammopathies, lymphoproliferative diseases, epidermoid malignancies, hypothyroidism, myeloproliferative disorders, and certain medications Topical thrombin, idiopathic, autoimmune diseases, procainamide Bronchogenic carcinoma, idiopathic Treatment FFP, rFVIIa FIX concentrates, APCCs, rFVIIa, corticosteroids FFP, FXI concentrates, rFVIIa, tranexamic acid, fibrin glue FXIII concentrate, FFP, stored plasma, cryoprecipitate Desmopressin, infusion of FVIII that contains vWF, IVIG, plasma exchange APCC, FFP
XI XIII VWF
II VII
FIX concentrates, APCC, FVIII concentrates, rFVIIa, fibrin glue, tranexamic acid X Amyloidosis, carcinoma, acute nonlymphocytic APCC, tranexamic acid, leukemia, acute respiratory infections, fungicide fibrin glue, FFP exposure, idiopathic APCCactivated prothrombin complex concentrate; FFPfresh frozen plasma; IVIG intravenous immunoglobulin; vWFvon Willebrand factor.
Epidemiology
United States statistics
The incidence of acquired hemophilia A has been estimated to be 0.2-1.0 case per 1 million persons per year, but this figure may underestimate the true incidence of the disorder, given the difficulty in making the diagnosis.[1] In addition, some patients with acquired hemophilia and low titers of inhibitors may not be diagnosed unless they undergo surgery or trauma, which also may lead to an underestimation of the incidence of the disease.[1] The incidence of acquired inhibitors to clotting factors other than factor VIII (FVIII) is unknown, although it is significantly lower than that reported with acquired hemophilia A.
International statistics
Acquired hemophilia has a worldwide distribution. In the United Kingdom, the incidence of acquired hemophilia has been reported to be 1.48 per million persons per year.[12] There is no known association between an increased susceptibility to develop acquired autoantibodies to coagulation factors and ethnicity.
Prognosis
Because it is frequently confused with other life-threatening conditions (eg, disseminated intravascular coagulation) and typically occurs in an elderly population, acquired hemophilia can lead to severe morbidity and even mortality before it is correctly diagnosed.[7] Estimates of the mortality associated with acquired hemophilia range from 7.9% to 22%, with most hemorrhagic deaths occurring within a few weeks of presentation.[1] More than 80% of patients with FVIII autoantibodies hemorrhage into the skin, muscles, or soft tissues and mucous membranes. Muscle bleeding episodes can be severe and can lead to compartment syndrome and tissue death.[7] Other manifestations include prolonged postpartum bleeding, excessive bleeding following surgery or trauma, and, occasionally, cerebral hemorrhage.[1, 17] In general, the prognosis of patients with acquired hemophilia depends on the patients response to immunosuppression.[1, 18, 12] A meta-analysis of 249 patients with acquired hemophilia found that 3 factors had an independent impact on overall survival and disease-free survival: related conditions (malignancy vs postpartum), complete remission status, and age at diagnosis (< 65 y vs 65 y).[18, 12] Survival was greatest in patients with postpartum inhibitors, in those who achieved complete remission, and in those who were younger than 65 years. In some patients, such as those with postpartum or drug-induced inhibitors, the inhibitors may disappear spontaneously within a few months of delivery or after the discontinuance of drug therapy.[1] In contrast, patients with associated autoimmune disorders usually have hightiter inhibitors that seldom resolve spontaneously or with monotherapy with steroids.[1] Patients with underlying malignancies may have a worse prognosis than patients without a malignancy.[18] Fifty percent to 70% of patients with underlying malignancies achieve complete eradication of the inhibitor.[1] Nonetheless, the inhibitor may not always disappear
despite successful treatment of the tumor. In addition, the reappearance of the inhibitor may not predict the recurrence of the malignancy. Approximately 20% of patients experienced a relapse after immunosuppressive therapy was discontinued. Relapse typically occurred between 1 week and 14 months after therapy was stopped.[12] This finding reinforces the need for long-term follow-up of patients with acquired hemophilia. Most patients who relapse (70%) achieve a second complete remission, although some may need long-term maintenance immunosuppression.[15]
Patient Education
Clinicians should conduct one-on-one discussions of issues with patients and family members. Because of the substantial risk of relapse, patients should be counseled to report signs of bleeding or bruising so that relapse can be detected as early as possible. Early recognition of relapse may minimize the time during which patients are at risk for hemorrhage.[12] Although pregnancy-related inhibitors tend not to recur in subsequent pregnancies in patients who achieve complete remission, women who experience pregnancy-related acquired hemophilia should be counseled about the possibility of recurrence in future pregnancies.[18]
History
Unlike patients with hereditary hemophilia, patients with acquired hemophilia do not have a personal or family history of bleeding episodes (see the image below).[1]
Clinical presentation of acquired hemophilia. About half of the cases are associated with other conditions, such as pregnancy, autoimmune disease, and cancer.[1, 10] The other cases are often idiopathic.
Physical Examination
The clinical picture of acquired hemophilia differs from that of hereditary hemophilia. For instance, intra-articular bleeding episodes, which are typical in congenital factor VIII (FVIII) deficiency complicated by the presence of alloantibodies, are unusual in patients with acquired hemophilia. Instead, hemorrhages into the skin, muscles, or soft tissues and mucous membranes occur in most patients.[1] Bleeding episodes are more frequent and severe in patients with acquired hemophilia than in patients with congenital hemophilia (see the image below).[12]
Sites of bleeding in patients with acquired hemophilia (n = 149). This research was originally published in Blood. Collins PW, Hirsch S, Baglin TP, et al. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation. Blood. 2007;109(5):1870-7. American Society of Hematology. The etiology underlying the difference in bleeding symptomatology between acquired and congenital hemophilia is unknown.[7] Typical signs of acquired hemophilia A include overt bleeding, epistaxis, gastrointestinal (GI) and urologic bleeding, and retroperitoneal hematomas.[1, 7, 4] Spontaneous bruising and muscle hematomas are most frequent.[2] If untreated, bleeding into the muscles may progress into a compartment syndrome, with compression of the neurovascular bundles. Subglottic hemorrhage may threaten the airway. Other frequent manifestations of acquired hemophilia include melena, hematuria, and iatrogenic bleeding, particularly after attempts to insert intravenous (IV) lines. Prolonged postpartum bleeding, excessive bleeding after trauma or surgery, and, occasionally, cerebral hemorrhage may also occur.[1]
Complications
Complications may be divided into hemorrhagic and nonhemorrhagic categories. Hemorrhagic complications include epistaxis, GI and urologic bleeding, retroperitoneal hematomas, compartment syndrome, prolonged postpartum bleeding, excessive posttraumatic or postoperative bleeding, subglottic or cerebral hemorrhage, and thrombocytopenia.[1, 2, 18] Adverse thrombotic events may also occur as a result of hemostatic therapy. Hemarthroses are rare. Nonhemorrhagic complications include the adverse effects of immunosuppression, such as infection, sepsis, and neutropenia.[18]
Diagnostic Considerations
Diagnosis of acquired hemophilia can be difficult, both because the condition is rare and because the patient does not have the usual personal or family history of bleeding episodes, such as is seen in congenital hemophilia.[1] Moreover, the clinical signs and symptoms of acquired hemophilia differ from those of hereditary hemophilia. In addition to the differentials (see below), conditions to be considered include the following:
Heparin administration
Lupus anticoagulant
Differentials
Approach Considerations
Treatment strategies for acquired hemophilia have 2 major objectives. During acute bleeding episodes, effective control of bleeding manifestations is the primary objective. However, the ultimate therapeutic goal is to eliminate the inhibitor and cure the disease. The treatments used to accomplish these objectives usually depend on the natural history of acquired hemophilia, the clinical presentation of the coagulopathy, and the titer of the inhibitor (expressed in Bethesda units [BU]).[1] Most patients with acquired hemophilia are older and may have many concomitant diseases, and, thus, may require an individualized therapeutic approach.[26] Frequently, treatment of the underlying disorder or the discontinuation of an offending drug may eliminate or assist in the eradication of the inhibitor.[7] Patients with acquired hemophilia A can bleed after negligible or minor trauma, and may even bleed spontaneously. Any physical activity may trigger bleeding in soft tissues. Until inhibitors are eradicated, patients with acquired hemophilia should avoid activities with a significant risk of trauma. Patients who have mild bleeding episodes may not require hemostatic therapy (see the image below). In these patients, immunosuppressive therapy should be initiated as soon as the diagnosis of acquired hemophilia is established, when indicated.[15]
Management of bleeding in acquired hemophilia. A study of practically all patients who presented with acquired hemophilia A in the United Kingdom over a 2-year period reported that the severity of bleeding did not correlate with
FVIII level or inhibitor titer and was not useful in predicting those patients who would have fatal bleeding or those who may not require hemostatic treatment.[12] Consequently, whether patients should receive hemostatic therapy should depend on their bleeding symptoms and not on their FVIII activity or inhibitor levels. However, considering inhibitor levels may be useful in selecting hemostatic therapy in patients who require it. Common treatments used in the management of patients with inhibitors to clotting factors other than factor VIII (FVIII) are listed elsewhere (see Etiology). Please see the following for more information:
venous hypercoagulability has been noted in individuals who received rFVIIa to prevent or treat bleeding complications associated with their acquired hemophilia.[34]
Combination therapy
Patients who do not respond to rFVIIa or APCC can either receive a combination of the 2 agents or undergo immunoadsorption/plasmapheresis (see below).[28] There is emerging evidence that in individuals with alloantibody-related bleeding who do not respond to either APCC or rFVIIa used alone, the combination of APCC with rVIIa may be useful. This combined approach has not been used systematically in acquired inhibitor patients; however, in off-label settings, it has been associated with high morbidity and mortality from thrombogenesis in adults. If combined therapy with APCC or rFVIIa is administered, clinicians should carefully monitor the patient for hypercoagulable complications.
Immunoadsorption or plasmapheresis
Temporary reduction of the inhibitor titer through extracorporeal removal of the autoantibody should be considered in patients with high inhibitor titers and severe hemorrhages and in those who do not respond to rFVIIa or APCC.[1]
Extracorporeal autoantibody removal can be accomplished by using therapeutic plasmapheresis or specific immunoadsorption of immunoglobulins.[1, 36, 37, 38, 39, 40] Unfortunately, no Sepharose columns are currently available in the United States to accomplish this. Immunoadsorption may be particularly useful when a rapid reduction in the inhibitor titer is required.[19] After plasmapheresis or immunoadsorption, FVIII replacement should be initiated to achieve hemostasis.[7]
Eradication of Inhibitor
Guidelines suggest that as soon as the diagnosis of acquired hemophilia is established, elimination of the inhibitor should be attempted by means of immunosuppression (see the image below).[15] Eradicating the inhibitor is important to restore normal hemostasis and minimize the patients risk of bleeding.[15] Patients who achieve complete remission (eradication of the inhibitor) have been shown to have a better outcome in terms of overall survival than patients who do not achieve complete remission.[18]
Eradication of the inhibitor for acquired hemophilia. In patients with mild hemorrhagic symptoms and low levels of inhibitors, immunosuppressive therapy may not be required to eliminate the inhibitor. About 25% of patients will achieve spontaneous remission without immunosuppression.[41] Drug-induced or pregnancy-associated autoantibodies frequently resolve spontaneously, whereas those associated with underlying autoimmune diseases rarely spontaneously resolve. [1] Because patients remain at risk for fatal bleeding until the inhibitor is eradicated, and there are no clinical laboratory features that identify all high-risk patients, all patients should be immunosuppressed as soon as the diagnosis is made.[12]
Steroids/cytotoxic therapy
First-line therapy for eradicating inhibitors usually includes methylprednisolone at a dose of 1 mg/kg/day (or an equivalent dose of prednisone), which results in the abolition of inhibitors in approximately 60-70% of patients.[15, 18] Adding oral cyclophosphamide 50-150 mg/d can increase the response rate to 70-80%.[15, 18] However, the overall survival and disease-free survival are the same for steroids as for steroids plus cytotoxic agents.[15, 18] Cyclophosphamide has also been administered IV at high intermittent doses. In addition, a nonrandomized study reported no difference between treatment with steroids alone and treatment with steroids plus cytotoxic agents.[12] Other cytotoxic agents that have been used
Because alkylating agents may cause infertility, alopecia, myelosuppression, and other adverse effects, prednisolone alone or combined with azathioprine may be preferred for patients with acquired hemophilia associated with pregnancy.[15] Response is typically seen in 3-6 weeks, but some patients may not show response for months.[10] Because relapse may occur when immunosuppression is stopped or reduced, premature discontinuance of therapy should be avoided.[7]
Targeted/biologic therapy
Rituximab, an anti-CD20 monoclonal antibody, has shown promising results in eradicating inhibitors in acquired hemophilia.[7, 45, 46, 47, 48] The usual dose is 375 mg/m2 each week for 4 weeks. Most responses are seen within 2 weeks.[7] The current consensus is that rituximab should be considered in patients who are resistant to first-line therapy or who cannot tolerate standard immunosuppressive therapy.[7] Some authors, however, have proposed that rituximab should be included as first-line therapy in combination with prednisone for patients whose inhibitor titers are higher than 5 but lower than 30 BU and in combination with prednisone and cyclophosphamide for patients whose titers are higher than 30.[47, 7] At present, there are no results from randomized controlled trials to confirm the usefulness of rituximab as a first-line or salvage therapy for acquired hemophilia.
Cyclosporine
Cyclosporine has been used as salvage therapy alone or with prednisolone, but it is particularly effective in patients with underlying systemic lupus erythematosus.[7] Because of cyclosporines toxicities and adverse effects, serum levels should be monitored. Successful treatment with cyclosporine can usually be discontinued after 1 year of therapy.
Intravenous immunoglobulin
Intravenous immunoglobulin (IVIG) may be useful as a second-line therapy for patients who do not initially respond to immunosuppression.[7] However, a large retrospective study showed no benefit when high-dose IVIG was added to prednisolone or cytotoxic agents.[15] Another study reported that adding IVIG to immunosuppressive regimens does not affect rates of complete remission and survival.[12] This should be reserved as first-line treatment for those with low antibody titers.
FVIII, and treatment appeared to achieve rapid remission in the vast majority of patients.[49] This approach is a potentially useful treatment option for those with severe bleeding.
of the tumor. However, the decision to initiate immunosuppressive therapy should take into account other factors (eg, patient age, malignancy type, and bleeding severity). Severe bleeding can occur from trivial injuries, intramuscular injections, intra-arterial blood sampling, and invasive procedures, all of which should be prevented.[18] To minimize the risk of bleeding in patients with acquired hemophilia, it is important to avoid situations that may place patients at high risk for bleeding, at least until they are in remission.
Medication Summary
Drugs that disturb platelet function, including aspirin and nonsteroidal anti-inflammatory agents (NSAIDs), and any herbal medications that can precipitate bleeding should be avoided until the inhibitor is eradicated. Medications used to treat acquired hemophilia include antihemophilic agents, corticosteroids, immunosuppressive agents, and monoclonal antibodies (mAbs).
Antihemophilic factor (Advate, Alphanate, Helixate FS, Hemofil M, HumateP, Koate-DVI, Kogenate FS, Monarc-M, Monoclate-P, Recombinate, ReFacto)
Factor VIII (FVIII) is a protein in normal plasma that is necessary for clot formation and hemostasis. It activates factor X (FX) in conjunction with activated factor IX (FIX); activated FX converts prothrombin to thrombin, which converts fibrinogen to fibrin, which, with factor XIII (FXIII), forms a stable clot. View full drug information
Recombinant factor VII (rVIIa) is indicated to treat bleeding episodes in patients with hemophilia A or B and inhibitors. It promotes hemostasis by activating the extrinsic pathway of the coagulation cascade, forming complexes with tissue factor, and promoting activation of FX to factor Xa, FIX to factor IXa, and factor II (FII) to factor IIa. rVIIa is indicated for treatment of bleeding episodes and for prevention of bleeding in surgical interventions or invasive procedures in patients with acquired hemophilia.
Main effect is enhancement of water reabsorption in the kidney and smooth muscle constriction. Causes dose-dependent increase in plasma FVIII and plasminogen activator.
Antihemophilic Agents
Class Summary
Antihemophilic agents are used for FVIII replacement therapy in patients with acquired hemophilia A. Appropriate monitoring is needed to manage active bleeding and to monitor and manage any allergic reactions that may develop during the infusion. View full drug information
Anti-inhibitor coagulant complex is used in patients with FVIII inhibitors. It can temporarily correct the coagulation defect of patients with inhibitors to FVIII; it is generally used in patients with inhibitor titers of 5 BU/mL or higher. The dose depends on patient weight, hemorrhage severity, inhibitor titer, and in vivo effect. The clinical effect on bleeding is the most important determinant of the dose and frequency of therapy. When inhibitors are present, dosage requirements are extremely variable and are determined by clinical response.
Corticosteroids
Class Summary
Corticosteroids have anti-inflammatory properties and cause profound and varied metabolic effects. They also modify the bodys immune response to diverse stimuli. View full drug information
Prednisolone is a delta 1-derivative of the naturally occurring adrenocortical steroids. It suppresses key components of the immune system.
Immunosuppressive Agents
Class Summary
Patients with autoimmune reactions, such as the development of inhibitors, often benefit from immunosuppression. View full drug information
Cyclophosphamide is chemically related to nitrogen mustards. It is an alkylating agent; the mechanism of action of active metabolites may involve cross-linking of DNA, which may interfere with the growth of normal and neoplastic cells. Cyclophosphamide may also be administered intravenously (IV) at doses up to 750 mg/m2 q3-4wk. View full drug information
Monoclonal Antibodies
Class Summary
Rituximab (anti-CD-20) monoclonal antibody binds to pre-B cells and mature B cells. It results in lymphocytotoxic effects to B cells, which should result in reduced autoantibody production. There are a small number of reports suggesting that immunosuppressed individuals receiving rituximab may be susceptible to developing progressive multifocal encephalopathy. Low leukocyte counts may also occur. View full drug information
Rituximab (Rituxan)
Rituximab is a genetically engineered chimeric murine/human mAb directed against the CD20 antigen found on surface of normal and malignant B lymphocytes. It is an immunoglobulin G1 (IgG1) kappa immunoglobulin containing murine light- and heavy-chain variable region sequences and human constant region sequences.